EUCTR2007-000854-30-ES进行中（未招募）不适用
Estudio aleatorizado, en doble ciego y controlado con placebo de una dosis fija de metilnaltrexona subcutánea en adultos con enfermedad avanzada y estreñimiento inducido por opiáceos: eficacia, seguridad y cuestionarios de salud adicionalesA Randomized, Double-Blind, Placebo-Controlled Study of a Fixed Dose of Subcutaneous Methylnaltrexone in Adults With Advanced Illness and Opioid-Induced Constipation: Efficacy, Safety, and Additional Health Outcomes
Wyeth Research Division of Wyeth Pharmaceuticals Inc., Global Medical Affairs0 个研究点目标入组 500 人开始时间: 2008年5月12日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •The subject:
- •1.Is a man or woman aged 18 years or older.
- •2.Has a diagnosis of advanced illness (ie, a terminal illness such as incurable cancer or other end-stage disease).
- •3.Has a life expectancy of = 1 month.
- •4.Is able to give informed consent and to answer patient-reported outcomes (PRO) questions by himself or herself.
- •5.Is receiving opioids, both
- •a.On a regular schedule, not just as-needed (PRN) or rescue doses, for the control of pain for at least 2 weeks before the first dose of test article, and
- •b.On a stable opioid regimen for at least 3 days before the first dose of test article. Stable” is defined as no reduction in dose of =50%. Increases to the opioid regimen are permitted.
- •6.Has a diagnosis of constipation, defined as either
- •a.Fewer than 3 bowel movements during the previous week by history, and no clinically notable laxation in the 24 hours before the first dose of test article, or
- •b.No clinically notable laxation in the 48 hours before the first dose of test article. Note: Small amounts of leakage” of liquid stool or pellets” may or may not be considered clinically notable, at the discretion of the investigator.
- •7.Has constipation further defined as opioid induced, as determined by the investigator.
- •8.Is on a stable laxative regimen for at least 3 days before the first dose of test article administration (eg, stool softener and senna or equivalent). This means that there must be a standing laxative order (not PRN).
- •a.A subject who meets inclusion criterion 6a and uses or used a rescue laxative (or enema/suppository) that produces a notable bowel movement within the 24 hours before the first dose of test article must wait to be laxation free for 24 hours in order to receive test article.
- •b.A subject who meets inclusion criterion 6b and receives or received a rescue laxative (or enema/suppository) that produces a notable bowel movement within the 24 hours before the first dose of test article must wait to be laxation free for 48 hours in order to receive test article.
- •Note: Rescue medications or rescue procedures for constipation may not be used within 4 hours before or 4 hours after test article administration.
- •9.Has stable vital signs, as determined by the investigator.
- •10.Has had an electrocardiogram (ECG) performed during the screening visit or within the 2 months before the screening visit. If an ECG is not performed specifically for this study, a copy of the previously recorded tracing must be obtained and stored in the source documents.
- •11.Has a negative urine pregnancy test result at screening (for women of presumed childbearing potential).
- •12.Must be surgically sterile, or must agree to use a medically acceptable method of birth control or practice sexual abstinence for the duration of the study and for 15 days after the last dose of test article (unless female and postmenopausal, ie, > 12 months since the last menstrual period).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •The subject:
- •1.Has received previous treatment with methylnaltrexone.
- •2.Has a known or suspected mechanical gastrointestinal obstruction.
- •3.Has any potential nonopioid cause of bowel dysfunction that in the opinion of the investigator might be a major contributor to the constipation.
- •4.Has current peritoneal catheter for intraperitoneal chemotherapy or dialysis.
- •5.Has clinically significant active diverticular disease as determined by the investigator.
- •6.Has evidence of fecal impaction either by physical examination or x-ray examination.
- •7.Has physical evidence of peritonitis.
- •8.Has a history of bowel surgery within 10 days before test article administration.
- •9.Has a fecal ostomy.
- •10.Has used vinca alkaloids (eg, vincristine, vinblastine, or vinorelbine) at any time during the 6 months before screening.
- •11.Has a body weight less than 38 kg.
- •12.Has a history of stage 4 or 5 chronic kidney disease (glomerular filtration rate [GFR] < 30 mL/min per 1.73 m2).
- •13.Has a known or suspected allergy to methylnaltrexone or other similar compounds (ie, naltrexone or naloxone).
- •14. Is participating or participated in studies involving investigational products within the 30 days before screening.
- •15.Is a woman who is pregnant and/or nursing.
- •16.Has any other clinically important abnormalities as determined by the investigator that may interfere with his or her participation in or compliance with the study.
研究者
相似试验
进行中（未招募）
1 期
Estudio aleatorizado, en doble ciego y controlado con placebo, de la eficacia y la seguridad de TAK-242 frente al placebo en sujetos con insuficiencia cardiovascular y respiratoria inducida por sepsisA Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety ofTAK-242 Versus Placebo in Subjects With Sepsis Induced Cardiovascular and Respiratory FailureShock séptico e insuficiencia respiratoriaSeptic shock and respiratory failure.MedDRA version: 9.1Level: PTClassification code 10040070Term: Septic shockMedDRA version: 9.1Level: PTClassification code 10038695Term: Respiratory failureEUCTR2007-005687-27-ESTakeda Global Research & Development Centre (Europe), Ltd.2,500
进行中（未招募）
1 期
Estudio aleatorizado, doble ciego y controlado con placebo con 3 grupos paralelos para evaluar la eficacia y la seguridad de linagliptina en dosis de 2,5 mg dos veces al día frente a 5 mg una vez al día durante 12 semanas como tratamiento adyuvante a un régimen de metformina dos veces al día en pacientes con diabetes mellitus tipo 2 y un control glucémico insuficienteA randomised double-blind, placebo-controlled, 3 parallel group study investigating the efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily over 12 weeks as add-on therapy to a twice daily dosing regimen of maximal metformin therapy in patients with type 2 diabetes mellitus and insufficient glycemic controlDiabetes tipo 2Type 2 diabetesMedDRA version: 12.0Level: LLTClassification code 10067585Term: Type 2 diabetes mellitusEUCTR2009-013549-27-ESBoehringer Ingelheim España, S.A.451
进行中（未招募）
不适用
Estudio aleatorizado, doble ciego y controlado con placebo de RAD001 en el tratamiento del angiomiolipoma en pacientes con Complejo de Esclerosis Tuberosa (CET) o linfangioleiomiomatosis esporádica (LAM)EUCTR2008-002113-48-ESovartis Farmacéutica, S.A.99
进行中（未招募）
1 期
Estudio aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de fesoterodina, como tratamiento añadido, en varones con síntomas persistentes de vejiga hiperactiva que reciben monoterapia con un alfabloqueante para los síntomas del tracto urinario inferior”A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TOEVALUATE THE EFFICACY AND SAFETY OF FESOTERODINE AS ANADD-ON THERAPY IN MEN WITH PERSISTENT OVERACTIVE BLADDERSYMPTOMS UNDER MONOTHERAPY OF ALPHA BLOCKER FOR LOWERURINARY TRACT SYMPTOMSEUCTR2007-004555-11-ESPfizer, S.A.900
进行中（未招募）
1 期
n estudio para evaluar la potencia, calidad de vida, efectos secundarios ytolerabilidad del tratamiento a largo plazo (24 semanas) con prucaloprida enpacientes con edad = 18 años con estreñimiento crónico.Chronic constipationEstreñimiento crónicoMedDRA version: 14.0Level: PTClassification code 10010774Term: ConstipationSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2011-000670-62-ESShire-Movetis NV340